Sodium Carbonate → HCID 90284557、化合物
反応式
[C:1]([O:5][C:6]([NH:8][C@H:9]1[CH2:14][CH2:13][CH2:12][CH2:11][C@H:10]1[NH:15][C:16]1[N:21]=[C:20](Cl)[C:19]2[C:23](=[O:33])[N:24]([C:26]([O:28][C:29]([CH3:32])([CH3:31])[CH3:30])=[O:27])[CH2:25][C:18]=2[C:17]=1[F:34])=[O:7])([CH3:4])([CH3:3])[CH3:2].[B-](F)(F)(F)[CH2:36][CH2:37][C:38]1[CH:43]=[CH:42][CH:41]=[CH:40][CH:39]=1.[K+].C(=O)([O-])[O-].[Na+].[Na+]>O1CCOCC1.O.Cl[Pd](Cl)([P](C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1)[P](C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1>[C:1]([O:5][C:6]([NH:8][C@H:9]1[CH2:14][CH2:13][CH2:12][CH2:11][C@H:10]1[NH:15][C:16]1[N:21]=[C:20]([CH2:36][CH2:37][C:38]2[CH:43]=[CH:42][CH:41]=[CH:40][CH:39]=2)[C:19]2[C:23](=[O:33])[N:24]([C:26]([O:28][C:29]([CH3:32])([CH3:31])[CH3:30])=[O:27])[CH2:25][C:18]=2[C:17]=1[F:34])=[O:7])([CH3:4])([CH3:3])[CH3:2]参加物
反応物 3
生成物 1
試薬・触媒・溶媒 3
反応条件
- 温度
- 85 °C
実験手順
In a 30 mL sealed cap glass vial, tert-butyl 6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate (150 mg, 0.301 mmol), potassium trifluoro(phenethyl)borate (76 mg, 0.361 mmol) and PdCl2(PPh3)2 (42.2 mg, 0.060 mmol) were dissolved in dioxane (5 mL). To the reaction mixture was added 2N aqueous sodium carbonate solution (2 mL). The cap was sealed and the reaction mixture was heated at 85° C. for 2 hours. The reaction mixture was subsequently diluted with water (5 mL) and extracted with EtOAc (2×30 mL). The combined organic phase was dried over sodium sulfate and evaporated to give the intermediate, tert-butyl 6-(((1R,2S)-2-((tert-butoxycarbonyl)amino)cyclohexyl)amino)-7-fluoro-3-oxo-4-phenethyl-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate, which was treated with TFA (4 mL) at room temperature for 1 hour to remove the protecting groups. TFA was subsequently evaporated from the reaction mixture. The residual material was dissolved in DMSO (8 mL) and purified by preparative HPLC, eluting with a gradient of 25-40% ACN (0.035% TFA) and water (0.05% TFA). The pure product fractions were combined, evaporated to a minimal volume, and lyophilized to give a TFA salt of the title compound as a white solid (21 mg, 19%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.41 (br s, 2H), 1.65 (br s, 2H), 1.68-1.81 (m, 2H), 1.84 (br s, 2H), 2.83-3.04 (m, 2H), 3.14-3.41 (m, 2H), 4.22-4.43 (m, 3H), 6.65 (d, J=6.82 Hz, 1H), 7.08-7.33 (m, 4H), 7.37 (br s, 1H), 7.54 (br s, 1H), 7.70 (br s, 3H), 8.31 (s, 1H). ESI-MS m/z [M+H]+ calc'd for C21H25FN4O, 369. found, 369.
後処理
- customIn a 30 mL sealed
- customThe cap was sealed
- extractionextracted with EtOAc (2×30 mL)
- dry with materialThe combined organic phase was dried over sodium sulfate
- customevaporated
出典と根拠
- ORDレコード
- ord-1c08caf8ebce4bd480c0ce4c371389fd
- 出典データセット
- uspto-grants-2015_06
- 特許番号
- US09056873B2
反応ノート
読み込み中…